<DOC>
	<DOCNO>NCT00002566</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It know whether combine chemotherapy bone marrow transplantation effective treatment men germ cell tumor . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy bone marrow transplantation treat men relapse germ cell tumor .</brief_summary>
	<brief_title>Combination Chemotherapy With Bone Marrow Transplantation Treating Men With Germ Cell Tumors</brief_title>
	<detailed_description>OBJECTIVES : I . Compare event-free survival male patient germ cell tumor relapse first partial remission treat salvage therapy comprise cisplatin , etoposide , ifosfamide ( PEI ) vinblastine , ifosfamide , cisplatin ( VeIP ) without high-dose carboplatin , etoposide , cyclophosphamide , follow autologous bone marrow and/or peripheral blood stem cell transplantation . OUTLINE : This randomize , multicenter study . Patients stratify accord prior complete remission first-line treatment ( yes v ) , primary site disease ( testicular v retroperitoneal v mediastinal ) , lung metastasis study entry ( yes v ) . Autologous bone marrow peripheral blood stem cell ( PBSC ) harvest . Part I ( salvage ) : Patients assign regimen A previously receive vinblastine part first-line treatment , cisplatin , vinblastine , bleomycin ( PVB ) cisplatin , cyclophosphamide , doxorubicin , vinblastine , bleomycin ( CISCA VB ) . Patients assign regimen B previously receive etoposide ( VP-16 ) part first-line treatment , bleomycin , VP-16 , cisplatin ( BEP ) . Regimen A : Patients receive cisplatin IV 2 hour , VP-16 IV 2 hour , ifosfamide IV 1 hour day 1-5 ( PEI ) . Regimen B : Patients receive cisplatin etoposide regimen A vinblastine IV day 1 2 ( VeIP ) . Treatment regimens continue every 3 week 2 course . Patients refractory disease day 43 take study . Part II : Patients randomize 1 2 treatment arm . Arm I : Patients receive 2 additional course PEI VeIP . Arm II : Patients receive 1 additional course PEI VeIP , follow 1 course high-dose carboplatin IV 2 hour , VP-16 IV 2 hour , cyclophosphamide IV 1 hour day 1-4 . Autologous bone marrow and/or PBSC reinfused day 7 fourth course patient arm . Patients arm residual disease fourth course may undergo surgery . PROJECTED ACCRUAL : A total 280 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis testicular extragonadal male germ cell tumor Must meet 1 follow condition completion platinumbased firstline chemotherapy : Complete remission ( CR ) follow relapse Partial remission ( PR ) Prior resection viable malignancy elevate tumor marker allow Initial bulky disease CR ( significantly reduce still abnormal plateau ) allow increase biological tumor marker development new metastasis Seminoma relapse CR PR cisplatinbased chemotherapy allow No pure seminoma pretreated carboplatin No refractory disease ( i.e. , document increase tumor burden and/or serum tumor marker level within 1 month platinumcontaining chemotherapy ) CNS involvement allow PATIENT CHARACTERISTICS : Age : 16 Sex : Male Performance status : WHO 02 OR Karnofsky 50100 % Life expectancy : No limit life expectancy due severe nonmalignant disease Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No severe cardiac disease would interfere study therapy Pulmonary : No severe pulmonary disease would interfere study therapy Other : HIV negative No severe neurologic metabolic disease would interfere study therapy No psychological , socioeconomic , geographic circumstance would preclude study No concurrent malignancy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy metastatic disease allow Surgery : See Disease Characteristics Prior surgery metastatic disease allow</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>extragonadal germ cell tumor</keyword>
</DOC>